Revolution Medicines, Inc. (RVMD)
RVMDNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$199.83
+7.55 (+3.93%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $43.29bn
- P/E
- –
- EPS, last 4 quarters
- $-8.39
- Dividend yield
- –
- Day range
- –
- 52-week range
- $58.91 to $224.31
- Average volume
- 2.10m
- Previous close
- $192.28
Analysts
25 coveringBuy23 buy, 2 hold, 0 sell
Targets a year out average $268.21, +34.2% from here
Earnings
next estimate $-1.57Next report
Dec 2025
-19.2%
Mar 2026
-25.1%
Jun 2026
-21.2%
Sep 2026
+18.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | $197.56m |
| Gross profit | – | – | – | $197.23m |
| Operating income | -$361.63m | -$445.22m | -$505.13m | -$373.15m |
| Net income | -$364.89m | -$453.82m | -$644.37m | -$407.46m |
News
8 latest- iShares Biotechnology ETF Experiences Big OutflowBNK Invest · 10 hours ago
- Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?The Motley Fool · 1 day ago
- Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer DrugThe Motley Fool · 1 day ago
- Revolution Medicines (RVMD) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque UptakeZacks · 4 days ago
- What Revolution Medicines (RVMD) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Revolution Medicines Reports Third Quarter 2026 Financial Results and RASONQUE LaunchFintel · 5 days ago
- Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
The company
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- revmed.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.